Lucentis and Visual acuity tests abnormal - a phase IV clinical study of FDA data

Summary:

Visual acuity tests abnormal is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lantus, and have Diabetic retinal oedema.

The phase IV clinical study analyzes which people have Visual acuity tests abnormal when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Visual acuity tests abnormal?

Visual acuity tests abnormal is found to be associated with 31 drugs and 130 conditions by eHealthMe. Check the latest studies of Visual acuity tests abnormal.

On Jun, 18, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 21 people (0.08%) have Visual acuity tests abnormal.

Could Lucentis cause Visual acuity tests abnormal?

Among these 21 people:

How long have people been on Lucentis when they have Visual acuity tests abnormal? *

What is the gender of people who have Visual acuity tests abnormal when taking Lucentis? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Visual acuity tests abnormal when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Visual acuity tests abnormal? *

Vision Blurred: 7 people, 33.33%
Visual Acuity Reduced (reduced clearness of vision): 5 people, 23.81%
Retinal Oedema (swelling of retina): 4 people, 19.05%
Eye Haemorrhage (bleeding in the eye): 4 people, 19.05%
Visual Impairment: 3 people, 14.29%
Blindness: 3 people, 14.29%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 3 people, 14.29%
Vitreous Floaters (spots before the eyes): 2 people, 9.52%
Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 9.52%
Eye Pain: 2 people, 9.52%

What are the existing conditions these people have? *

Retinal Vessel Occlusion (a blockage in one of the small arteries): 6 people, 28.57%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 6 people, 28.57%
Retinal Vascular Occlusion (a blockage of the small veins that carry blood away from the retina): 2 people, 9.52%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 9.52%
Age-Related Macular Degeneration: 2 people, 9.52%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 4.76%
Eye Inflammation: 1 person, 4.76%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Visual acuity tests abnormal?

- Check whether Visual acuity tests abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual acuity tests abnormal:

Visual acuity tests abnormal (31 drugs)

Browse all the conditions that are associated with Visual acuity tests abnormal:

Visual acuity tests abnormal (130 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.